Immunotherapy of B lymphoma by anti-idiotype antibodies: characterization of variant tumour cells appearing a long time after the initial tumour inoculation
- PMID: 1760810
- PMCID: PMC11038697
- DOI: 10.1007/BF01741323
Immunotherapy of B lymphoma by anti-idiotype antibodies: characterization of variant tumour cells appearing a long time after the initial tumour inoculation
Abstract
Immunotherapy of a murine B-cell lymphoma by antibodies to idiotypic determinants of its IgM, resulted in surviving tumour-free mice. Several of these mice, however, did develop tumours a long time after the initial inoculation of the tumour cells, or upon rechallenge of the survivors with B-lymphoma cells. The presence of tumour cells during this long latent period may have been due to the development in the host of an anti-idiotype immune response. These late-developing tumours were detected by a radioimmunoassay and characterized by immunofluorescent staining and sodium dodecyl sulphate/polyacrylamide gel electrophoresis. Cells of some late-developing tumours lost the idiotype recognized by the antibodies used for the immunotherapy. Several of these tumours expressed IgM on the cell surface, while others did not, because of the absence of light chains. They were identical in the structure of their rearranged mu chain genes proving their derivation from the original inoculation. Cell lines obtained from the late-developing tumours differed in their tumorigenicity. The appearance of idiotype-negative tumour cells as a result of anti-idiotype immunotherapy has a great impact in our efforts to cure lymphoma by this modality.
Similar articles
-
Rejection of tumors of the B cell lineage by idiotype-vaccinated mice.Cancer Immunol Immunother. 1999 Feb;47(6):330-6. doi: 10.1007/s002620050538. Cancer Immunol Immunother. 1999. PMID: 10203063 Free PMC article.
-
Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin.Immunol Cell Biol. 2008 Mar-Apr;86(3):261-7. doi: 10.1038/sj.icb.7100153. Epub 2008 Jan 15. Immunol Cell Biol. 2008. PMID: 18195726
-
Monoclonal antibodies raised against the idiotype of the murine B cell lymphoma, BCL1 act primarily with heavy chain determinants.Hybridoma. 1991 Apr;10(2):219-27. doi: 10.1089/hyb.1991.10.219. Hybridoma. 1991. PMID: 1908435
-
Induction of B cell tumor dormancy by anti-idiotypic antibodies.Curr Opin Immunol. 1993 Oct;5(5):740-4. doi: 10.1016/0952-7915(93)90130-k. Curr Opin Immunol. 1993. PMID: 8240736 Review.
-
Therapeutic idiotype vaccines in B lymphoproliferative diseases.Expert Opin Biol Ther. 2004 Jun;4(6):959-63. doi: 10.1517/14712598.4.6.959. Expert Opin Biol Ther. 2004. PMID: 15174977 Review.
Cited by
-
Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell-surface idiotype and the costimulatory B7 molecule.Cancer Immunol Immunother. 1995 Oct;41(4):236-42. doi: 10.1007/BF01516998. Cancer Immunol Immunother. 1995. PMID: 7489566 Free PMC article.
References
-
- Ber R, Eriksson I. Isolation of ouabain-resistant human lymphoblastoid cell lines by multi-step selection. Mutat Res. 1979;61:411. - PubMed
-
- Bergman Y, Haimovich J. Characterization of a carcinogeninduced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol. 1977;7:413. - PubMed
-
- Bergman Y, Haimovich J. B-lymphocytes contain three species of µ chains. Eur J Immunol. 1978;8:876. - PubMed
-
- Berinstein N, Levy R. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL-2. J Immunol. 1987;139:971. - PubMed
-
- Campbell MJ, Esserman L, Levy R. Immunotherapy of established murine B cell lymphoma. J Immunol. 1988;141:3227. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials